Literature DB >> 23979154

Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.

George J Broze1, Thomas J Girard.   

Abstract

In a report reading like a fascinating detective story, Vincent and colleagues crack the mysterious case of east Texas bleeding disorder. They show that affected individuals have a mutation in exon 13 of the coagulation F5 gene that causes increased expression of an alternatively spliced transcript, which encodes a previously unrecognized factor V (FV) isoform they call FV-short. This FV isoform lacks a large portion of the B domain of FV, which is normally released upon the proteolytic activation of FV by thrombin and binds tightly to the coagulation regulator tissue factor pathway inhibitor-α (TFPIα). This interaction leads to an approximately 10-fold increase in the level of TFPIα circulating in plasma and a resultant anticoagulant effect that produces a hemorrhagic diathesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979154      PMCID: PMC3754277          DOI: 10.1172/JCI71220

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin.

Authors:  D D Monković; P B Tracy
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

2.  The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.

Authors:  Matthew Ndonwi; Elodee A Tuley; George J Broze
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

3.  Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas.

Authors:  S Q Kuang; S Hasham; M D Phillips; D Wolf; Y Wan; P Thiagarajan; D M Milewicz
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

4.  Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma.

Authors:  E Castoldi; P Simioni; D Tormene; J Rosing; T M Hackeng
Journal:  J Thromb Haemost       Date:  2009-11-30       Impact factor: 5.824

5.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

6.  Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.

Authors:  Tilman M Hackeng; Kristin M Seré; Guido Tans; Jan Rosing
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-17       Impact factor: 11.205

7.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.

Authors:  G J Broze; L A Warren; W F Novotny; D A Higuchi; J J Girard; J P Miletich
Journal:  Blood       Date:  1988-02       Impact factor: 22.113

8.  Activation of human factor V by factor Xa and thrombin.

Authors:  D D Monkovic; P B Tracy
Journal:  Biochemistry       Date:  1990-02-06       Impact factor: 3.162

9.  Kinetics of factor Xa inhibition by tissue factor pathway inhibitor.

Authors:  Z F Huang; T C Wun; G J Broze
Journal:  J Biol Chem       Date:  1993-12-25       Impact factor: 5.157

10.  Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase.

Authors:  A E Mast; G J Broze
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

View more
  8 in total

Review 1.  Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.

Authors:  Antonio Girolami; Elisabetta Cosi; Silvia Ferrari; Annamaria Lombardi; Fabrizio Fabris
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.

Authors:  Kanagasabai Vadivel; Sathya-Moorthy Ponnuraj; Yogesh Kumar; Anne K Zaiss; Matthew W Bunce; Rodney M Camire; Ling Wu; Denis Evseenko; Harvey R Herschman; Madhu S Bajaj; S Paul Bajaj
Journal:  J Biol Chem       Date:  2014-09-28       Impact factor: 5.157

Review 3.  Platelets: Context-Dependent Vascular Protectors or Mediators of Disease.

Authors:  Randal Westrick; Gabrielle Fredman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-07       Impact factor: 8.311

Review 4.  New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice.

Authors:  A Girolami; E Cosi; S Ferrari; A M Lombardi; B Girolami
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

Review 5.  The interrelationship between pregnancy, venous thromboembolism, and thyroid disease: a hypothesis-generating review.

Authors:  Stine Linding Andersen; Kasper Krogh Nielsen; Søren Risom Kristensen
Journal:  Thyroid Res       Date:  2021-05-25

6.  The contribution of TFPIα to the hemostatic response to injury in mice.

Authors:  Tanya T Marar; Nicholas D Martinez; Susan A Maroney; Amy E Siebert; Jie Wu; Timothy J Stalker; Maurizio Tomaiuolo; Sinny Delacroix; Robert D Simari; Alan E Mast; Lawrence F Brass
Journal:  J Thromb Haemost       Date:  2021-07-14       Impact factor: 16.036

Review 7.  Interplay between platelets and coagulation.

Authors:  Yaqiu Sang; Mark Roest; Bas de Laat; Philip G de Groot; Dana Huskens
Journal:  Blood Rev       Date:  2020-07-12       Impact factor: 10.626

8.  Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.

Authors:  Björn Dahlbäck; Li Jun Guo; Ruzica Livaja-Koshiar; Sinh Tran
Journal:  Res Pract Thromb Haemost       Date:  2017-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.